Similar Virologic and Immunologic Efficacy With Fosamprenavir Boosted With 100 mg or 200 mg of Ritonavir in HIV-Infected Patients: Results of the LESS Trial

Cohen, Calvin; DeJesus, Edwin; LaMarca, Anthony; Young, Benjamin; Yau, Linda; Patel, Lisa; Vavro, Cindy; Wire, Mary Beth; Wannamaker, Paul; Shaefer, Mark
September 2010
HIV Clinical Trials;Sep/Oct2010, Vol. 11 Issue 5, p239
Academic Journal
Purpose: Ritonavir (RTV) effectively boosts most protease inhibitors but is associated with significant dose-dependent adverse events (AEs). In an effort to better manage toxicities through a reduced dose of RTV, this study compared fosamprenavir (FPV) boosted with RTV 100 mg (FPV/r100) or with RTV 200 mg (FPV/r200) daily. Methods: This 24-week, open-label study enrolled patients taking a FPV/r200-containing regimen who had HIV RNA <400 copies/mL and randomized them 1:2 to continue that regimen or simplify to FPV/r100 once daily. Other medications were not altered. The primary endpoint was the percentage of patients without suspected or confirmed virologic failure (HIV RNA ≥⃒400 copies/mL) through week 24 by a missing/discontinuation equals failure (M/D=F) analysis. Noninferiority criteria were demonstrated if the lower bound of the 95% confidence interval (CI) for the difference in the primary endpoint rates between groups was greater than -12. Results: The 2 regimens met prespecified noninferiority criteria (FPV/r100, 92%; FPV/r200, 94%; 95% CI, -9.36 to 5.12). At week 24, the percentage of patients with HIV RNA <50 copies/mL by M/ D=F was 83% in the FPV/r100 group and 85% in the FPV/r200 group. Drug-related grade 2-4 AEs were uncommon (FPV/r100, 4%; FPV/r200, 7%). Median changes in lipids were similar in both groups, with the exception of triglycerides (FPV/r100, -21 mg/dL; FPV/r200, -2 mg/dL). Conclusions: This 24-week study demonstrated that among previously suppressed patients, once-daily FPV/r100 was similar to FPV/r200 in virologic and immunologic effects but was associated with greater decreases from baseline in triglyceride levels.


Related Articles

  • Directly Administered Antiretroviral Therapy for HIV-Infected Individuals in Opioid Treatment Programs: Results from a Randomized Clinical Trial. Lucas, Gregory M.; Mullen, Bernadette Anna; Galai, Noya; Moore, Richard D.; Cook, Katie; McCaul, Mary E.; Glass, Sheldon; Oursler, Krisann K.; Rand, Cynthia // PLoS ONE;Jul2013, Vol. 8 Issue 7, p1 

    Background: Data regarding the efficacy of directly administered antiretroviral therapy (DAART) are mixed. Opioid treatment programs (OTPs) provide a convenient framework for DAART. In a randomized controlled trial, we compared DAART and self-administered therapy (SAT) among HIV-infected...

  • Antiretroviral Drug Dosing Errors in HIV-Infected Patients Undergoing Hemodialysis. Tourret, Jérôme; Tostivint, Isabelle; Du Montcel, Sophie Tézenas; Karie, Svetlana; Launay-Vacher, Vincent; Vigneau, Cécile; Bessette, Christel; Deray, Gilbert; Bagnis, Corinne Isnard // Clinical Infectious Diseases;9/15/2007, Vol. 45 Issue 6, p779 

    Background. Several studies have revealed the frequency of antiretroviral (ARV) drug prescription errors. We analyzed highly active antiretroviral therapy (HAART) prescribing practices for human immunodeficiency virus (HIV)-infected patients undergoing hemodialysis in France. Methods. Prescribed...

  • Characteristics of HIV infected adolescents in Latin America: results from the NISDI pediatric study. Santos Cruz, Maria Leticia; Freimanis Hance, Laura; Korelitz, James; Aguilar, Adriana; Byrne, Julianne; Serchuck, Leslie K.; Hazra, Rohan; Worrell, Carol; NISDI Pediatric Study Group 2010 // Journal of Tropical Pediatrics;Jun2011, Vol. 57 Issue 3, p165 

    Objective: HIV-infected adolescents are a heterogeneous population; source of infection, immunodeficiency severity and antiretroviral (ARV) experience vary. Here, we describe youth followed in an observational study at Latin American sites of the NICHD International Site Development...

  • Discontinuation of Antiretroviral Therapy in Patients with Chronic HIV Infection: Clinical, Virologic, and Immunologic Consequences. Mata, Rosario C.; Viciana, Pompeyo; de Alarcón, Arístides; López-Cortés, Luis F.; Gómez-Vera, Josefa; Trastoy, Mónica; Cisneros, José M. // AIDS Patient Care & STDs;Sep2005, Vol. 19 Issue 9, p550 

    To investigate the clinical, virologic and immunologic consequences of planned treatment interruptions in chronically HIV-infected patients. One hundred forty-one patients with undetectable viral load for at least 6 months and CD4+ T cells count greater than 500 per microliter were recruited....

  • Plasma Nevirapine Levels and 24-Week Efficacy in HIV-Infected Patients Receiving Nevirapine-Based Highly Active Antiretroviral Therapy with or without Rifampicin. Manosuthi, Weerawat; Sungkanuparph, Somnuek; Thakkinstian, Ammarin; Rattanasiri, Sasivimol; Chaovavanich, Achara; Prasithsirikul, Wisit; Likanonsakul, Sirirat; Ruxrungtham, Kiat // Clinical Infectious Diseases;7/15/2006, Vol. 43 Issue 2, p253 

    Seventy human immunodeficiency virus (HIV)-infected patients receiving rifampicin and 70 HIV-infected patients not receiving rifampicin were enrolled to receive 400 mg of nevirapine-based highly active antiretroviral therapy per day. Mean plasma nevirapine levels at 8 and 12 weeks were lower in...

  • Recent HIV-1 Infection: To Treat or Not to Treat, That Is the Question. Tossonian, Harout; Conway, Brian // Journal of Infectious Diseases;1/1/2012, Vol. 205 Issue 1, p10 

    The author reflects on a study conducted by C. Hogan and colleagues' setpoint study, a randomized clinical trial in which patients who had been infected with HIV in the previous six months were assigned to receive a 36-week course of antiretroviral therapy. The study's principal end point was a...

  • The Virological and Immunological Characteristics of the HIV-1-Infected Population in Brazil: From Initial Diagnosis to Impact of Antiretroviral Use. Diaz, Ricardo Sobhie; Inocêncio, Lilian A.; Sucupira, Maria Cecilia Araripe; Pereira, Anderson Alvarenga; Hunter, James; Ferreira, João Eduardo; Araújo, Luciano V.; Souza, Denise F. C.; Sabino, Ester Cerdeira // PLoS ONE;10/28/2015, Vol. 10 Issue 10, p1 

    Background: Immunological and virological status of HIV-infected individuals entering the Brazilian public system over time was analyzed. We evaluated the impact of ART on virological, immunological and antiretroviral resistance over time. Methods: CD4+ T cell counts, viral loads and genotypes...

  • Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children.  // AIDS Research & Therapy;2011, Vol. 8, p40 

    The article reports on a study that examines the incidence rate of immunologic failure (IF) and virologic failure (VF) after first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Thai HIV infected children. It states clinical and laboratory parameter...

  • Raltegravir may be effective for adolescents with HIV.  // Infectious Disease News;Oct2009, Vol. 22 Issue 10, p27 

    The article discusses a study which investigated the effectiveness and safety of Raltegravir in patients with HIV aged 12 to 18 years.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics